GlobeNewswire Inc | Feb 16, 2021 07:00AM EST

February 16, 2021

DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinanttherapies forgastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer, will present at The Microcap Rodeo Winter Wonderland Conference taking place virtually from February 16-19, 2021.

During his live virtual presentation on February 17th at 4:30 p.m., Eastern Time, Mr. Sapirstein will provide an overview of AzurRxs business and clinical development programs and discuss anticipated 2021 milestones. Additionally, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors.

Details of the presentation are as follows:

Event: The Microcap Rodeo Winter Wonderland ConferenceDate: February 17, 2021Time: 4:30 p.m. Eastern TimeRegistration: https://microcaprodeo.com/signupPresentation: https://www.webcaster4.com/Webcast/Page/2134/40075

About AzurRx BioPharma, Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate isMS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor;FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients andFW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida. with clinical operations in Hayward, California. For more information visitwww.azurrx.com.

Forward-Looking StatementsThis press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Companys actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; and the impact of the coronavirus (COVID-19) pandemic on the Companys operations and current and planned clinical trials, including potential delays in clinical trial recruitment and participation. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Companys financial results are contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2019 under the headingRisk Factors,as well as the Companys subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

AzurRx BioPharma, Inc.1615 South Congress AvenueSuite 103Delray Beach, Florida 33445Phone: (646) 699-7855info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC.Hans Vitzthum, Managing Director1 International Place, Suite 1480Boston, MA 02110Phone: (617) 430-7578hans@lifesciadvisors.com

Media contact:

Tiberend Strategic Advisors, Inc.Johanna Bennett/Ingrid Mezo(212) 375-2665/(646) 604-5150jbennett@tiberend.com/imezo@tiberend.com